These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18924267)

  • 1. [No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk].
    Slagman MC; Waanders F; Navis GJ
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2150-1; author reply 2151. PubMed ID: 18924267
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the renal response to ace inhibition: a strategy toward more effective long-term renoprotection.
    Navis G; de Jong PE; de Zeeuw D
    Adv Nephrol Necker Hosp; 1997; 27():57-66. PubMed ID: 9408442
    [No Abstract]   [Full Text] [Related]  

  • 6. When hypertension and diabetes coexist: strategies for cardiorenal protection.
    Weber MA
    Postgrad Med; 2000 Oct; 108(5 Suppl):12-8. PubMed ID: 19667536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA; Epstein BJ; Roberts ME
    J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors for the prevention and treatment of cardiovascular disease.
    Frishman WH
    Heart Dis; 2000; 2(3):183-4. PubMed ID: 11794142
    [No Abstract]   [Full Text] [Related]  

  • 10. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update.
    Arici M; Erdem Y
    Am J Kidney Dis; 2009 Feb; 53(2):332-45. PubMed ID: 19166800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
    Kalaitzidis R; Bakris G
    Postgrad Med; 2009 Mar; 121(2):77-88. PubMed ID: 19332965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New perspectives for patients at risk for atherosclerosis. The importance of ACE inhibitors in cardiovascular prevention].
    Landgraf W; Klein HH
    Pharm Unserer Zeit; 2003; 32(1):36-44. PubMed ID: 12577759
    [No Abstract]   [Full Text] [Related]  

  • 14. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
    Probstfield J
    J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
    Papademetriou V
    Am Heart J; 2009 Jun; 157(6 Suppl):S24-30. PubMed ID: 19450721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypertension in patients with diabetes].
    Poulsen PL; Hansen KW; Gaede PH; Rossing P
    Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction.
    Jose P; Tomson C; Skali H; Rouleau J; Braunwald E; Arnold JM; Cuddy T; Sussex B; Bernstein V; Pfeffer M; Solomon S
    J Am Coll Cardiol; 2006 Apr; 47(8):1725-7. PubMed ID: 16631015
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitors for all--'Hope' for the heart and failure for the kidneys?
    Goldsmith D
    J Hum Hypertens; 2001 Mar; 15(3):147-51. PubMed ID: 11317197
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.